| Objective:To evaluate the clinical efficacy and survival analysis of thoracoscopy associated with radiofrequency ablation in the treatment of non-small cell lung cancer by observing the effectiveness,indicators of tumor size,number and position and the survival analysis follow-up at 3 months after treatment in order to provide a basis for the treatment of non-small cell lung cancer.Methods:To choose 200 patients with non-small cell lung cancer who who did not have the radical operation of lung cancerdiagnosed the Third Affiliated Hospital and had complete pathological diagnosis and data.The patients who complianced with research condition and be included in the treatment group and the patients with advanced chemotherapy were formed in the control group.The treatment group was treated with thoracoscopic radiofrequency ablation and the control group was treated with chemotherapy.To collect the basic information about the age,sex and occupation of the treatment group and control group in order to compare the effectiveness,indicators of tumor size,number and position before and after treatment and analysis of the survival analysis follow-up at 3 months after treatment.To evaluate the clinical efficacy and survival analysis of thoracoscopy associated with radiofrequency ablation in the treatment of non-small cell lung cancer by all indicators.Results:The treatment group was more effective than the control group(87.00% vs.57.00%,P<0.001).The treatment group was better than the control group(P<0.001).There was no difference of PS score for patients before treatment between two groups.The difference of PS score was statistically significant after treatment between two groups(t=-3.274,P<0.05).The PS score of the control group was lower than the control group.The difference of PS score was statistically significant before and aftertreatment for the treatment group and the control group(P<0.05).The effective rate of the treatment group was more than the control group for evaluating by PS score(87.0% vs.67.0%,P<0.05).The proportion of fever of the treatment group was more than the control group after treatment(58.0% vs.70.0%,P<0.05).The differences of fever for patients between the two groups were statistically significant(P<0.001).The differences of the level of Pa O2,Pa CO2,FVC,FEV1 and DLCO of the treatment group was more than the control group after treatment(t=3.126,t=3.155, t=11.410,t=4.058,t=12.120,P<0.05).The follow-up time was 6-18 months and the average value was(13.36±3.12)months until Jun.30.2017.The survival rate of Progression-Free-Survival for 6 months was 92.00%,the survival rate of Progression-Free-Survival for 1 year was 72.00%.The survival rate of Progression-Free-Survival for 6 months of the treatment group was longer than the control group(89.00% vs.77.00%,P<0.05).The survival rate of Progression-Free-Survival for 1 year of the treatment group was longer than the control group(79.0% vs.63.0%,P<0.05).It showed that the treatment method,clinical stage and distant metastasis have effect on survival rate by univariate analysis.It showed that the effect of treatment and distant metastasis were affected for the survival rate by introducing the distant recurrence,pathological classification and clinical staging as independent variables into the COX regression model.The risk of death caused by radiofrequency ablation with thoracoscope is 0.21 times that of the conventional chemotherapy,and the risk of distant metastasis of tumor is 10.42 times of that of distant metastasis.The difference of survival time was statistically significant for two groups by log-rank test(?2=8.379,P<0.05).The difference of clinical stage and distant metastasis was statistically significant for the treatment group by log-rank test(?2=27.622,P<0.05).Conclusion:1.The effective rate of patients treat by thoracoscopic radiofrequency ablation is more effective than treat with chemotherapy.The effective rate of patients with stage ?B is the most and the PS score of patients treat by thoracoscopic radiofrequency ablation is more effective than treat with chemotherapy.2.The difference of the incidence of adverse reaction(fever,nausea and vomit,hemoglobin,leukopenia,thrombocytopenia and neutropenia)of non-small cell lung cancer patientsis no statistically significant between thoracoscope guided radiofrequency ablation combined with standard chemotherapy treatment and standard chemotherapy.3.The use of thoracoscope-guided radiofrequency ablation combined with conventional chemotherapy for non-small cell lung cancer patients with 6-month progression-free survival and 1-year progression-free survival were higher than conventional chemotherapy in patients with recent clinical efficacy is better.4.The risk of death caused by radiofrequency ablation with thoracoscope is 0.21 times that of the conventional chemotherapy,and the risk of distant metastasis of tumor is 10.42 times of that of distant metastasis. |
PDF Full Text Request